Rationale: Sympathetic nervous system control of inflammation plays a central role in hypertension. The gut receives significant sympathetic innervation, is densely populated with a diverse microbial ecosystem, and contains immune cells that greatly impact overall inflammatory homeostasis. Despite this uniqueness, little is known about the involvement of the gut in hypertension.
T he Centers for Disease Control estimates that hypertension contributes to ≈1000 American deaths each day. 1, 2 Hypertension is the most modifiable risk factor for cardiovascular disease and stroke and also plays an important role in obesity, diabetes mellitus, and metabolic syndrome. 3 Despite advances in blood pressure (BP) control, ≈15% of hypertensive patients remain resistant to available lifestyle modifications and pharmacotherapy. [4] [5] [6] [7] [8] Neurogenic components have been implicated as a cause of resistant hypertension, as evidenced by measurements of sympathetic outflow and norepinephrine overflow. 8, 9 Specifically, altered autonomic nervous system activity and associated increases in peripheral and neuroinflammation have been implicated in the pathogenesis of resistant hypertension. 8, 10, 11 Our recent evidence, demonstrating increased peripheral and neuroinflammation in hypertension as a result of autonomic influences on bone marrow (BM) activity, further supports this concept. 12 However, the specific mechanism of autonomic dysregulation in hypertension pathophysiology remains elusive.
It has become evident in recent years that a symbiotic relationship exists between the gut and its microbiota for regulation of both local gut and systemic immunity. 13, 14 Imbalances in this host-gut microbiota eubiosis are potentially of major pathophysiological consequence to the host. For example, imbalances in this symbiotic relationship have been associated with diverse diseases, such as obesity, nervous system disorders, chronic kidney disease, inflammatory bowel disease, and cardiovascular disease. 14, 15 However, the involvement of the host-gut relationship in hypertension has yet to be investigated in detail despite the fact that (1) the gut is the most highly innervated peripheral organ, with significant numbers of the motor fibers to the gut identified as sympathetic nerves. 16 It is pertinent to note that elevated sympathetic nervous system activity is a hallmark of both animal and human hypertension 8, 9 ; (2) autonomic nervous system influences gut permeability, 17 inflammatory state, 18 and microbial communities in inflammatory bowel disease and other diseases 19 ; (3) gut microbial products, such as short chain fatty acids, lipopolysaccharides, and neurotransmitters influence both the immune and vascular systems 20, 21 ; and (4) studies from our group and others have demonstrated a link between gut dysbiosis and hypertension. 22, 23 This evidence, taken together, led us to the following hypothesis: increased sympathetic activity to the gut alters gut pathology in such a way that is conducive to increased gut permeability, altered inflammatory status, and microbial dysbiosis impacting BM production of proinflammatory cells. Thus, we propose that hypertension is, at least in part, a result of pathophysiological changes in the gut. The present study was designed to provide experimental evidence to support or refute this hypothesis.
Methods
All animal procedures were approved by the University of Florida Institutional Animal Care and Use Committee. Full details of all experimental protocols are presented in the Methods section in the Online Data Supplement.
Results

Alterations in Gut Pathology in Rat Models of Hypertension
First, we investigated whether the integrity of the gut epithelial barrier is altered in the spontaneously hypertensive rat (SHR) model using various techniques: (1) oral fluorescein isothiocyanate-dextran for epithelial permeability, (2) an innovative Multi-Scale Indention System to measure gut wall stiffness, 24, 25 and (3) Western blotting for tight junction proteins. Both young prehypertensive and adult SHR with established hypertension along with age-matched, normotensive Wistar-Kyoto rats (WKY) were used to investigate gut associations with BP ( Figure 1A ). We observed a 2.1-fold increase in fluorescein isothiocyanate-dextran accumulation in adult SHR plasma ( Figure 1B; What Is Known?
• Increased sympathetic activity, inflammation, and gut dysbiosis in hypertension.
• Gut houses largest number of immune cells and trillions of microorganisms.
• The central nervous system-immune system communication is altered in hypertension.
What New Information Does This Article Contribute?
• Hypertension is associated with increased gut wall permeability, altered tight junction proteins and fibrosis, decrease in goblet cells and shorter villi, and microbial dysbiosis.
• Angiotensin-converting enzyme inhibitor, captopril, which lowers blood pressure in spontaneously hypertensive rat, reverses gut pathology.
• Sympathetic nerve activity and tight junction proteins, but not gut wall pathology and microbial composition, are altered in prehypertensive animals.
Abundant evidence reveals that both sympathetic nervous system and inflammation are key players in the development and establishment of hypertension. The gastrointestinal tract, which houses the largest number of immune cells in the body and contains trillions of microorganisms, is emerging as an important organ in the maintenance of normal body homeostasis. Despite this, the involvement of gut in blood pressure control and hypertension is not known. This coupled with recent evidence of gut microbial dysbiosis in hypertension led us to test the following hypothesis in this study: sympathetic nervous system impacts gut physiology to maintain blood pressure homeostasis; its increased activity is associated with increased gut wall permeability, pathology, and dysbiosis in hypertension. We demonstrate that gut wall was significantly thicker, more permeable, fibrotic, and had less numbers of goblet cells and stunted villi in hypertensive animals. These changes in the gut were associated with increase in the sympathetic nerve activity to the gut. Angiotensin-converting enzyme inhibitor treatment lowered blood pressure and attenuated gut pathology. Further investigation into the mechanism of this proposed dysfunctional sympathetic-gut communication is necessary to evaluate the potential of gut and microbiota as novel targets with the use of pro-and prebiotics as combination therapy for drug-resistant hypertension.
Novelty and Significance been associated with an increase in tissue stiffness (effective modulus). 26 Accordingly, using the Multi-Scale Indention, we observed a 2.7-and 3.0-fold (P<0.05) increase in stiffness in the small intestine and proximal colon, respectively, in the adult SHR when compared with age-matched WKY ( Figure 1C and 1D) . However, no change was observed between young WKY and prehypertensive SHR. Next, we compared tight junction proteins by Western blotting. Levels of Ocln (occludin), Tjp1 (tight junction protein 1), and Cldn4 (claudin 4) were decreased by 46.3% (P<0.05), 22.5% (P<0.05), and 45.4% (P<0.05), respectively, in the small intestine of adult SHR compared with that of adult WKY ( Figure 1E and 1F) . Comparable decreases were observed in Ocln, Tjp1, and Cldn4 of the proximal colon in adult SHR ( Figure 1G and 1H) Figure 1G and 1H) . Similarly, the small intestine of prehypertensive SHR showed a 24% decrease in Ocln (P<0.05), 36.9% in Tjp1 (P<0.05), 34.7% in Cldn4 (P<0.05), and 39.9% in Cgn (P<0.05; Figure 1E and 1F). These observations support the suggestion that decreases in gut tight junction proteins may precede increases in gut permeability, stiffness, and high BP.
To investigate whether gut permeability is compromised in another model of hypertension, we evaluated the angiotensin II (Ang II)-infusion rat model of hypertension (Online Figure IA ). An increase in plasma fluorescein isothiocyanatedextran (Online Figure IB) was observed in Ang II-infused rats that was comparable to adult SHR, suggesting enhanced gut permeability. However, mean effective modulus was not significantly changed in this model (Online Figure IC and ID) . Protein levels of tight junctional proteins were also reduced in both small intestine and proximal colon of Ang II-infused rats (Online Figure IE and IH). For example, Tjp1 decreased by 48% (P<0.01) and 46% (P<0.05) and Cgn by 43% (P<0.01) and 49% (P<0.001) in small intestine and proximal colon, respectively. Ocln was decreased by 55% (P<0.01) only in the proximal colon. Although the differences between the SHR and Ang II-infusion models are evident, these observations suggest that both rat hypertension models exhibit an increase in gut permeability and decrease in tight junction proteins. Next, we investigated whether the observed increased permeability is associated with alterations in gut pathology in the SHR. Figure 2A through 2P depicts changes in the SHR small intestine compared with normotensive WKY rats, in both young and adult rats. We observed an 1.8-fold increase in fibrotic area in the adult SHR ( 
Effects of Angiotensin-Converting Enzyme Inhibition (Captopril) on Gut Pathology in the SHR
We investigated the effects of captopril, an effective antihypertensive medication in SHR, 27 to further explore the relationships between gut pathology and high BP. Adult WKY and SHR were treated with captopril for 4 weeks, which significantly reduced mean arterial pressure in SHR ( Figure 3A ; 170±5 mm Hg water versus 119±7 mm Hg captopril; P<0.01), with only a slight reduction in mean arterial pressure in WKY (110±9 mm Hg water versus 85±5 mm Hg captopril; P=0.071). Angiotensin-converting enzyme (ACE)-inhibition-related BP reduction was associated with a decrease in gut permeability in the SHR ( Figure 3B ; 1273±212 ng/mL versus 685±124 ng/mL; P<0.05), whereas no change was observed in WKY. Although effective modulus seems to be reduced in both the small intestine and proximal colon of captopril-treated SHR ( Figure 3C and 3D) , the values did not reach significance. We found a complete reversal in both fibrotic area ( Figure 3E through 3H and 3U; P<0.001) and thickness of the muscularis layer ( Figure 3I through 3L and 3V; P<0.01) with ACE-inhibition-related decreased BP in SHR. Although this did not prevent the reduction in goblet cell numbers ( Figure 3M through 3P and 3W), the villi length increased by 55% with ACE-inhibition reduced BP in treated SHRs (Figures 3Q through 3T and 3X; P<0.01). These data suggest that ACE inhibition-related decreased BP has beneficial effects on hypertensionlinked gut pathology.
Increase in Gut Inflammation in Hypertension
Real time-PCR revealed that Cd68 ( Figure 4A ) and Cd3e ( Figure 4B ) gene expression, representative of macrophages and T cells, respectively, was elevated in both the small intestine (1.8-and 2.7-fold, respectively) and proximal colon (1.9-and 6.2-fold, respectively) in the SHR (P<0.05). An increase in inflammatory status was further confirmed by levels of cytokine mRNAs ( Figure 4C and  4D) . The mRNA levels of interleukin 1β and high mobility group box 1 were 75% and 57% higher, respectively, in the SHR small intestine (P<0.05; Figure 4C ). In the proximal colon, we observed a 70% and 108% increase in interleukin 1β and tumor necrosis factor-α mRNA levels in the SHR ( Figure 4D ). No differences in high mobility group box 1 levels were observed in the colon between the 2 strains. Next, we investigated the mRNA levels of 3 proposed receptors for high mobility group box 1 28, 29 : toll-like receptor 2, toll-like receptor 4, and receptor for advanced glycation end-products, in view of accumulating evidence that gut high mobility group box 1 plays a critical role in systemic and gut inflammation 30 ( Figure 4E and 4F) . Furthermore, these receptors are implicated in inflammation induced by bacterial products. 31 We observed increases in mRNAs for both toll-like receptor 4 (46%) and receptor for advanced glycation end-products (303%) in the small intestine ( Figure 4E ) and colon (35% and 135%, respectively; Figure 4F ), whereas toll-like receptor 2 was increased 130% only in the SHR colon ( Figure 4F; P<0.05) .
Our previous studies have demonstrated that hypertension impacts BM activity by influencing proliferation, mobilization, and differentiation of hematopoietic stem cells. 32 This cellular response contributes to increased peripheral and neuroinflammation in hypertension. 33 Thus, we sought to determine whether altered BM cell activity contributes to increases in proinflammatory cells in the gut in hypertension using the chronic Ang II-infusion rat model. Enhanced green fluorescent protein (GFP) Sprague-Dawley BM chimeric rats were generated and subjected to a 4-week Ang II infusion (200 ng/kg per minute). 33 This infusion resulted in a significant increase in mean arterial pressure (saline, 95±2 mm Hg versus Ang II infusion, 150±3 mm Hg; P<0.001). The hypertensive response to Ang II infusion in enhanced GFP-chimeric rats was comparable to naive Sprague-Dawley rats. 33 We observed significant numbers of green fluorescent cells in the small intestine and colon of both the saline and Ang II-treated rats (Online Figure III) . However, levels of these BM-derived enhanced GFP + cells were 2.2-and 1.3-fold higher in small intestine and colon, respectively, of Ang II-treated rats compared with saline. Double staining with inflammatory markers documented an increase in CD3 + T cells, CD68 + macrophages, and Iba1 + macrophages in Ang II-treated rats (Online Figure IV) . Quantification revealed increases of 103% in CD3 + T cells, of 278% in CD68 + macrophages, and of 101% in Iba1 + macrophages in the small intestine of Ang II-treated rats. Similar increases were observed in the colon of the Ang IItreated animals. In contrast, no significant changes in number of cells double-stained for neurons (NeuN antibody) and smooth muscle cells (smooth muscle actin-α antibody) were observed comparing the 2 groups (data not shown). Taken together, these data indicate that the increase in inflammatory cells in hypertension is, in part, a result of mobilization of BM cells to gut.
Gut Perfusion Is Decreased in Hypertension
We compared the blood perfusion of the gut in WKY and SHR using Laser Spackle Contrast Imaging 33 and observed a significant decrease in mesenteric blood flow normalized to BP, in a section of small intestine in anesthetized adult WKY and SHR ( Figure 5 ). This interesting observation is consistent with reports indicating that decreased gut blood flow is associated with proinflammatory gut pathophysiology.
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Altered Microbial Community in Hypertensive Rat Gut
The above data indicate that hypertension is associated with increases in gut permeability and inflammatory status. These findings led us to investigate whether there are also differences in gut bacterial taxa between the normotensive WKY and SHR. Our previous data indicated a significant increase in the ratio of the Firmicutes to Bacteroidetes (F/B ratio, an indicator of gut microbial dysbiosis) phyla in the gut of SHR versus WKY. 22 Here, we examined whether this shift in F/B ratio is associated with the SHR strain or the development of hypertension in the SHR strain. We found that the F/B ratio in prehypertensive SHR is not different from age-matched WKY ( Figure 6A ). This finding supports the suggestion that the BP increase in the SHR is closely associated with the development of gut dysbiosis. Of the total number of genera represented in the gut microbiota, members of 25 most abundantly represented genera were compared in the prehypertensive SHR and the age-matched WKY using a heat map ( Figure 6B ), The heat map did not show any clustering between SHR and WKY, indicating that the abundance levels of selected genera in prehypertensive SHR were not significantly different from the agematched WKY.
Fecal bacterial analysis was done to determine specific bacterial genera that may be associated with the observed changes in permeability and inflammation in the adult SHR. We observed a significant increase in Gram-positive Streptococcus genus and Streptococcaceae family in the gut of the SHR, both belonging to the order of Lactobacillales (lactic acidproducing bacteria) and the phylum of Firmicutes ( Figure 6C , in red). This was consistent with changes we had previously observed in the Ang II-infusion hypertensive rodent model. 22 Furthermore, we observed a significant decrease in the Bifidobacterium genus and the related Bifidobacteriaceae family of Actinobacteria phyla ( Figure 6C, in green) , a Gram-positive bacterium with probiotic properties. 35, 36 We also observed a decrease in several bacterial genera of the Bacteroidetes phyla. These changes begin to pinpoint specific bacterial genera with implications in inflammation and hypertension.
Dysfunctional Autonomic-Gut Communication in Hypertension
Activity of the splanchnic sympathetic nerve innervating gut in young 4-week-old normotensive rats and SHR was determined using a decerebrated artificially perfused rat preparation ( Figure 7A ) as established previously. 37 This in situ preparation revealed classic phrenic nerve inspiratory (I) and expiratory (E) activity patterns (black trace) and robust splanchnic sympathetic nerve activity (red trace; Figure 7B ) in both groups. We observed a shift in the peak of splanchnic sympathetic nerve activity (red arrow) from the E phase in normotensive rats to the I phase in hypertensive rats, typical of the respiratory-sympathetic uncoupling pattern in other neuronal beds of hypertensive rodent models. 12, [38] [39] [40] Furthermore, a bolus intra-arterial challenge with 0.1 mL of 0.03% KCN showed a significant increase in the immediate increase in splanchnic sympathetic nerve activity bursting pattern in the hypertensive rats only (by ≈25% versus pre-KCN baseline; Figure 7C and 7D), consistent with augmented chemoreflex sensitivity and typical of elevated sympathetic responses in hypertensive rodent models. 39 This response was consistent over several preparations.
To confirm that the elevated sympathetic drive continues into established hypertension, we performed pseudorabies virus expressing GFP retrograde labeling from the gut in adult SHR and Ang II-infused rats. Application of pseudorabies virus-GFP to proximal colon and small intestine showed significant GFP fluorescent labeling in neurons of the paraventricular nucleus of the hypothalamus in SHR and WKY rats infused with Ang II subcutaneously within 4 days ( Figure 8A through 8C ), but not in WKY controls within the same time period and following a similar experimental protocol. These responses were consistent across several animals. Finally, we observed an increase in density of tyrosine hydroxylase immunoreactivity (1.8±0.2 WKY, 4.9±0.9 SHR; P<0.05) and a doubling in the mean intensity of tyrosine hydroxylase fluorescence in the small intestine of SHR (Figure 8D through 8F; P<0.05 ). These observations Figure 7 . Elevated splanchnic sympathetic nerve activity in the spontaneously hypertensive rat (SHR). A, In situ decerebrated artificially perfused rat preparation (schematics on the left) reveals respiratory uncoupling of the B, splanchnic sympathetic nerve activity (sSNA; red trace) in the hypertensive (HT) SHR compared with normotensive (NT) control rats. Phrenic nerve activity (PNA, black trace) inspiratory (I) and expiratory (E) phases were used to determine respiratory uncoupling. Note the typical shift in the peak of sSNA burst from the E phase in the NT (left, red arrow) to the I phase of PNA in the HT (right, red arrow). C and D, Intra-arterial bolus KCN injection produced a ≈25% higher sSNA burst from baseline (pre-KCN) in the HT compared with NT rats (n=5 per group). *P<0.05 baseline HT vs post-KCN HT. PP indicates pulse pressure.
confirmed augmented paraventricular nucleus-gut connectivity in both adult SHR and Ang II-infusion hypertension models.
Discussion
Our study demonstrates important changes in the gut in 2 rodent models of hypertension, suggesting a gut link with hypertension. The major findings are as follows: (1) increased permeability of gut epithelial barrier and inflammatory state is associated with BP elevation; (2) enhanced sympathetic neuronal communication between the paraventricular nucleus and gut; and (3) a shift in gut microbial genera is likely associated with the pathophysiological and immune status of the gut and high BP. Together, these changes could be important in the initiation and establishment of hypertension.
Additional significance of our study is the association of gut pathology and microbial dysbiosis with hypertension, and data from prehypertensive SHR are relevant in support of this concept. They show that changes in sympathetic nerve activity and gut tight junction proteins precede changes in gut pathology, dysbiosis, and hypertension. This view is further supported by ACE-inhibition-induced BP lowering in the SHR, which reversed gut pathology. It is pertinent to note that sympathetic tone in SHR is also attenuated by ACE-inhibition. 41, 42 Therefore, one cannot deduce whether changes in the gut pathology are BP or sympathetic activity driven or dependent on both. Further experiments would be needed to resolve this. Our data suggest that prohypertensive signals are perceived in the paraventricular nucleus and transmitted via central neural pathways to increase sympathetic activity and norepinephrine release to the gut. This could lead to alterations of gut junction proteins resulting in permeability changes, dysbiosis, and pathology. Chronic elevation of tyrosine hydroxylase in the gut of SHR, a key enzyme in norepinephrine generation, is consistent with this contention. In addition, gut dysbiosis and lactate-producing bacterial populations are increased in hypertensive rats. 22, 43 These bacteria also generate a variety of neurotransmitters themselves (eg, serotonin, 44 dopamine, 45 and histamine 46 ) that may potentially be involved in BP regulation. Furthermore, carbohydrates fermented by Streptococcus predominately yield lactic acid as a major end-product. 47 Lactic acid can potentially contribute to the modulation of the immune system in both gut and circulation. 48, 49 Support for this view comes from our experimental findings that (1) the lactic acid-producing bacterial population is increased in the SHR and Ang II-infusion rat hypertension model, 22 (2) increased inflammation in the small intestine and colon of hypertensive animals was associated with both the increase in F/B ratio and hypertension development, and (3) increased peripheral inflammation is associated with hypertension. 33 The increase in gut inflammatory cells in hypertension observed in this study could be a result of activation of resident immune cells or their infiltration from the BM. Although the resident immune cells undergo regular turnover, our data indicate that increased recruitment of BM inflammatory cells into the gut plays an important role in hypertension-associated gut inflammation in addition to the resident immune cells. The mechanism of this increase remains to be elucidated, but it could be a result of stimulation and recruitment of inflammatory cells by a shift in bacterial release of short chain fatty acids 50, 51 and direct autonomic nervous system-mediated regulation of BM inflammatory cell activity, as shown previously. 12 Interestingly, gut microbiota reportedly promote Ang II-related hypertension, as germ-free mice are protected from Ang II-induced vascular dysfunction and hypertension, 52 an effect suggested to be mediated by a dampened immune response.
The brain can also influence intestinal homeostasis by gut motility and mucus secretion. Involvement of mucus in mucosal immune responses is well recognized. 13 Our data demonstrate pathological changes in the gut of hypertensive animals. This includes increased permeability, flexibility and leakiness, fibrosis, and muscular tissues in the gut wall. In addition, stunted villi and decreased goblet cells were observed in both rat hypertension models. Goblet cells produce mucins, which protect the gut from pathogen invasion, thereby regulating gut immune responses. 13 A decrease in goblet cells in hypertensive animals could be associated with decreased mucin, contraction of mucin-degrading bacterial population, and potential expansion of other more harmful bacterial populations. Consequently, some commensal bacterial taxonomic branches are decreased in SHR and enriched in WKY rats. These include, Bacteriodetes-Alistipes, Bacteriodetes-Bacteroides, and Actinobacteria-Bifidobacterium branches that potentially impact gut immune status.
Recently, we advanced a brain-gut-BM axis hypothesis and proposed dysfunctional brain-gut interactions in hypertension. 7 Our current study, demonstrating an increased sympathetic drive associated with gut pathology and microbial dysbiosis, provides new evidence in support of that proposal. However, our findings generate questions for future investigation. For example, (1) does sympathetic activation precede or accompany changes in the gut? We favor the former scenario based on evidence that increases in sympathetic drive precede increases in BP in both animal models and human hypertension, 10 and our data presented here showing elevated sympathetic drive is present before pathological changes in the gut. (2) Does microbial dysbiosis promote hypertension? Recent fecal transplantation studies suggest that this is highly likely. 52, 53 ( 3) It is pertinent to recognize the well-established role of the afferent parasympathetic arm in the paradigm of gut-brain axis. 54, 55 Evidence indicates that microbiota communication with the brain involves afferent vagal signaling pathways, 56 and its activation modulates both neurochemical and behavioral effects. A recent report has described the role of the vagal anti-inflammatory pathway in modulation of intestinal muscularis layers and resident macrophages. 57 Considering that vagal activity is dampened in rodent models of hypertension, 10 it is possible that the shift in the balance of sympathetic and parasympathetic influences in the gut, rather than exaggerated sympathetic drive alone, contribute to hypertension-associated gut pathophysiology, dysbiosis, and immune system activation. Finally, therapeutic implications of this study for human hypertension must be investigated and clinical study (NCT 02188381) is underway.
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